Intrajejunal levodopa versus conventional therapy in parkinson disease: Motor and nonmotor effects

Prashanth Reddy, Pablo Martinez-Martin, Alexandra Rizos, Anne Martin, Guy C. Faye, Ian Forgacs, Per Odin, Angelo Antonini, K. Ray Chaudhuri

Research output: Contribution to journalArticle

Abstract

Seventeen patients with advanced Parkinson disease (PD) were treated with intrajejunal L-dopa infusion (IJL) and compared with a matched group of 9 patients (termed comparator [C]) not given IJL because of funding restriction by primary care trusts (PCTs) in the UK, although considered to be clinically eligible for IJL. Assessments were baseline and follow-up (6 months) with Hoehn and Yahr staging, unified PD rating scale (UPDRS-III and UPDRS-IV), Parkinson disease questionnaire (PDQ-8, quality of life [QoL]) and nonmotor symptom scale (NMSS).Baseline characteristics were comparable between the groups. The IJL-treated group showed highly significant improvements in UPDRS-III (P = 0.005), UPDRS-IV (P = 0.0004), total NMSS score (P = 0.004), and QoL (P = 0.01), whereas the C group showed no change in these parameters. A large effect size of IJL was seen in treated patients for UPDRS-III (1.13), UPDRS-IV (1.52), NMSS score (0.82), and QoL (1.12), whereas continuing conventional treatment registered no effect in C.This study confirms the robust effect of IJL on motor and, in particular, nonmotor symptoms and QoL in advanced PD as described in open-label studies but additionally points to the need for such treatment in those denied this therapy because of centrally dictated funding policies leading to inequalities in health care.

Original languageEnglish
Pages (from-to)205-207
Number of pages3
JournalClinical Neuropharmacology
Volume35
Issue number5
DOIs
Publication statusPublished - Sep 2012

Fingerprint

Levodopa
Parkinson Disease
Quality of Life
Therapeutics
Healthcare Disparities
Primary Health Care
Research Design

Keywords

  • intrajejunal L-dopa infusion
  • motor
  • nonmotor
  • Parkinson disease
  • quality of life

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology
  • Clinical Neurology

Cite this

Reddy, P., Martinez-Martin, P., Rizos, A., Martin, A., Faye, G. C., Forgacs, I., ... Chaudhuri, K. R. (2012). Intrajejunal levodopa versus conventional therapy in parkinson disease: Motor and nonmotor effects. Clinical Neuropharmacology, 35(5), 205-207. https://doi.org/10.1097/WNF.0b013e3182613dea

Intrajejunal levodopa versus conventional therapy in parkinson disease : Motor and nonmotor effects. / Reddy, Prashanth; Martinez-Martin, Pablo; Rizos, Alexandra; Martin, Anne; Faye, Guy C.; Forgacs, Ian; Odin, Per; Antonini, Angelo; Chaudhuri, K. Ray.

In: Clinical Neuropharmacology, Vol. 35, No. 5, 09.2012, p. 205-207.

Research output: Contribution to journalArticle

Reddy, P, Martinez-Martin, P, Rizos, A, Martin, A, Faye, GC, Forgacs, I, Odin, P, Antonini, A & Chaudhuri, KR 2012, 'Intrajejunal levodopa versus conventional therapy in parkinson disease: Motor and nonmotor effects', Clinical Neuropharmacology, vol. 35, no. 5, pp. 205-207. https://doi.org/10.1097/WNF.0b013e3182613dea
Reddy, Prashanth ; Martinez-Martin, Pablo ; Rizos, Alexandra ; Martin, Anne ; Faye, Guy C. ; Forgacs, Ian ; Odin, Per ; Antonini, Angelo ; Chaudhuri, K. Ray. / Intrajejunal levodopa versus conventional therapy in parkinson disease : Motor and nonmotor effects. In: Clinical Neuropharmacology. 2012 ; Vol. 35, No. 5. pp. 205-207.
@article{35e30fc51d3748b7bffbccac0a62ce89,
title = "Intrajejunal levodopa versus conventional therapy in parkinson disease: Motor and nonmotor effects",
abstract = "Seventeen patients with advanced Parkinson disease (PD) were treated with intrajejunal L-dopa infusion (IJL) and compared with a matched group of 9 patients (termed comparator [C]) not given IJL because of funding restriction by primary care trusts (PCTs) in the UK, although considered to be clinically eligible for IJL. Assessments were baseline and follow-up (6 months) with Hoehn and Yahr staging, unified PD rating scale (UPDRS-III and UPDRS-IV), Parkinson disease questionnaire (PDQ-8, quality of life [QoL]) and nonmotor symptom scale (NMSS).Baseline characteristics were comparable between the groups. The IJL-treated group showed highly significant improvements in UPDRS-III (P = 0.005), UPDRS-IV (P = 0.0004), total NMSS score (P = 0.004), and QoL (P = 0.01), whereas the C group showed no change in these parameters. A large effect size of IJL was seen in treated patients for UPDRS-III (1.13), UPDRS-IV (1.52), NMSS score (0.82), and QoL (1.12), whereas continuing conventional treatment registered no effect in C.This study confirms the robust effect of IJL on motor and, in particular, nonmotor symptoms and QoL in advanced PD as described in open-label studies but additionally points to the need for such treatment in those denied this therapy because of centrally dictated funding policies leading to inequalities in health care.",
keywords = "intrajejunal L-dopa infusion, motor, nonmotor, Parkinson disease, quality of life",
author = "Prashanth Reddy and Pablo Martinez-Martin and Alexandra Rizos and Anne Martin and Faye, {Guy C.} and Ian Forgacs and Per Odin and Angelo Antonini and Chaudhuri, {K. Ray}",
year = "2012",
month = "9",
doi = "10.1097/WNF.0b013e3182613dea",
language = "English",
volume = "35",
pages = "205--207",
journal = "Clinical Neuropharmacology",
issn = "0362-5664",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Intrajejunal levodopa versus conventional therapy in parkinson disease

T2 - Motor and nonmotor effects

AU - Reddy, Prashanth

AU - Martinez-Martin, Pablo

AU - Rizos, Alexandra

AU - Martin, Anne

AU - Faye, Guy C.

AU - Forgacs, Ian

AU - Odin, Per

AU - Antonini, Angelo

AU - Chaudhuri, K. Ray

PY - 2012/9

Y1 - 2012/9

N2 - Seventeen patients with advanced Parkinson disease (PD) were treated with intrajejunal L-dopa infusion (IJL) and compared with a matched group of 9 patients (termed comparator [C]) not given IJL because of funding restriction by primary care trusts (PCTs) in the UK, although considered to be clinically eligible for IJL. Assessments were baseline and follow-up (6 months) with Hoehn and Yahr staging, unified PD rating scale (UPDRS-III and UPDRS-IV), Parkinson disease questionnaire (PDQ-8, quality of life [QoL]) and nonmotor symptom scale (NMSS).Baseline characteristics were comparable between the groups. The IJL-treated group showed highly significant improvements in UPDRS-III (P = 0.005), UPDRS-IV (P = 0.0004), total NMSS score (P = 0.004), and QoL (P = 0.01), whereas the C group showed no change in these parameters. A large effect size of IJL was seen in treated patients for UPDRS-III (1.13), UPDRS-IV (1.52), NMSS score (0.82), and QoL (1.12), whereas continuing conventional treatment registered no effect in C.This study confirms the robust effect of IJL on motor and, in particular, nonmotor symptoms and QoL in advanced PD as described in open-label studies but additionally points to the need for such treatment in those denied this therapy because of centrally dictated funding policies leading to inequalities in health care.

AB - Seventeen patients with advanced Parkinson disease (PD) were treated with intrajejunal L-dopa infusion (IJL) and compared with a matched group of 9 patients (termed comparator [C]) not given IJL because of funding restriction by primary care trusts (PCTs) in the UK, although considered to be clinically eligible for IJL. Assessments were baseline and follow-up (6 months) with Hoehn and Yahr staging, unified PD rating scale (UPDRS-III and UPDRS-IV), Parkinson disease questionnaire (PDQ-8, quality of life [QoL]) and nonmotor symptom scale (NMSS).Baseline characteristics were comparable between the groups. The IJL-treated group showed highly significant improvements in UPDRS-III (P = 0.005), UPDRS-IV (P = 0.0004), total NMSS score (P = 0.004), and QoL (P = 0.01), whereas the C group showed no change in these parameters. A large effect size of IJL was seen in treated patients for UPDRS-III (1.13), UPDRS-IV (1.52), NMSS score (0.82), and QoL (1.12), whereas continuing conventional treatment registered no effect in C.This study confirms the robust effect of IJL on motor and, in particular, nonmotor symptoms and QoL in advanced PD as described in open-label studies but additionally points to the need for such treatment in those denied this therapy because of centrally dictated funding policies leading to inequalities in health care.

KW - intrajejunal L-dopa infusion

KW - motor

KW - nonmotor

KW - Parkinson disease

KW - quality of life

UR - http://www.scopus.com/inward/record.url?scp=84866559190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866559190&partnerID=8YFLogxK

U2 - 10.1097/WNF.0b013e3182613dea

DO - 10.1097/WNF.0b013e3182613dea

M3 - Article

C2 - 22821063

AN - SCOPUS:84866559190

VL - 35

SP - 205

EP - 207

JO - Clinical Neuropharmacology

JF - Clinical Neuropharmacology

SN - 0362-5664

IS - 5

ER -